Scientists rename Polycystic Ovary Syndrome in bid to halt delayed diagnoses
PCOS is often misunderstood due to its name's overemphasis on ovarian cysts, they say
www.independent.co.ukThe latest major development is a global push to rename Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), arguing the old name can be misleading and may contribute to delayed diagnosis and stigma.[1][3]
What the rename is (and why)
- The proposal is reported as changing “PCOS” to “PMOS” to better reflect that the condition involves hormonal (“polyendocrine”) and metabolic (“metabolic”) issues—not just ovaries or cysts.[3][1]
- News coverage also summarizes the rationale as addressing the concern that many patients diagnosed with PCOS may not actually have ovarian cysts, making the “polycystic” label potentially inaccurate.[2][3]
Timeline / when it’s expected to take effect
- Coverage states the transition is planned over time, with full implementation expected in the 2028 international guideline update (with a gradual rollout before then).[1][2]
Where it was announced
- The change was reported around May 2026, including discussion at/around the European Congress of Endocrinology in Prague.[2]
If you want, tell me whether you’re looking for (1) patient-facing summaries, (2) clinician/science details from the consensus statement, or (3) what this might mean for how symptoms/diagnosis are talked about—then I’ll tailor the latest roundup.